3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Red Blood Cells Transfusion
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Multiple Myeloma
1
Motor Activity
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Anemia
1
Interventions
Cyclophosphamide
32
Tacrolimus
29
fludarabine
27
Mycophenolic Acid
23
fludarabine phosphate
22
Busulfan
19
Whole-Body Irradiation
18
Melphalan
16
Methotrexate
15
Antilymphocyte Serum
14
Rituximab
12
Bortezomib
11
Stem Cell Transplantation
10
Cyclosporine
10
thymoglobulin
9
Sirolimus
9
Granulocyte Colony-Stimulating Factor
9
Peripheral Blood Stem Cell Transplantation
8
Thiotepa
7
Interviews as Topic
7
Filgrastim
7
Dexamethasone
7
Clofarabine
7
Blood Specimen Collection
6
Alemtuzumab
6
merphos
5
Voriconazole
5
Standard of Care
5
Nivolumab
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hematologic Neoplasms
×
Erythrocyte Transfusion
×
Clear all
NCT01237639
2016-10-12
TRIST
Ottawa Hospital Research Institute
Phase 3
Completed
300 enrolled